Valproate bismuth

Generic Name: Valproate bismuth

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₄₅BiO_₆

CAS Number: 60364-28-5

Unique Ingredient Identifier: 87PTX621FI

Overview

Valproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.

Indication

No indication information available.

Associated Conditions

Anginal Pain
Gingivostomatitis
Laryngitis
Pharyngitis
Sore Throat
Tonsillitis

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial	2025/07/16	NCT07068607	Not Applicable	Recruiting	Yongquan Shi
Tegoprazan-Based Dual Therapy With Amoxicillin vs Tetracycline for H. Pylori Eradication	2025/05/18	NCT06977841	Not Applicable	Not yet recruiting	Zhongshan Hospital (Xiamen), Fudan University
Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study	2024/12/12	NCT06731023	N/A	Not yet recruiting	Xiuli Zuo
Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.	2024/09/19	NCT06603688	Phase 4	Recruiting	Xijing Hospital of Digestive Diseases
Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication	2024/07/23	NCT06514274	Phase 4	Completed	Xijing Hospital of Digestive Diseases
Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy	2023/12/13	NCT06168084	Phase 4	Completed	Yongquan Shi
Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin	2023/06/23	NCT05915871	Phase 1	Completed	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology	2023/02/24	NCT05742568	Phase 4	Completed	Xijing Hospital of Digestive Diseases
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy	2022/02/11	NCT05237115	Phase 4	Completed	Xijing Hospital of Digestive Diseases
Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication	2021/08/20	NCT05014334	Phase 4	Completed	Xijing Hospital of Digestive Diseases

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Metox	Deseret Biologicals, Inc.	43742-1312	ORAL	12 [hp_X] in 1 mL	5/27/2025
MetDetox	Dr. Donna Restivo DC	62185-0062	ORAL	12 [hp_X] in 1 mL	5/23/2025

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
HOMEODEX 06	distributions biodentcom inc.	02232211	Drops - Oral	5 CH	6/3/1998
NEO-LARYNGOBIS	teva canada limited	00065927	Suppository - Rectal	135 MG	12/31/1950
BISMUTHUM METALLICUM GRANULES 5CH-30CH	dolisos laboratoires s.a.	00767743	Tablet - Oral	4 CH / TAB	12/31/1987
HOMEOPATHIC MEDICINE (S#76)- 30C LIQ	total health centre	02104822	Liquid - Sublingual	30 C / ML	12/31/1994
BISMUTH MET DPS 8D	dolisos laboratoires s.a.	00727857	Drops - Oral	8 X / X	12/31/1987
BISMUTHUM METALLICUM	dolisos canada inc.	02234351	Globules , Granules , Liquid - Oral	6 X	1/5/1998
NEO LARYNGOBIS ENF	lab bio chimique inc.,division of technilab pharma inc.	00065919	Suppository - Rectal	67.5 MG	12/31/1950
BISMUTUM METALLICUM-INJEEL FORTE LIQ (6D,10D,30D,200D/1.1ML)	Biologische Heilmittel Heel Gmbh	02070545	Liquid - Oral	6 D / 1.1 ML	12/31/1994
BISMUTUM METALLICUM-INJEEL LIQ (10D,30D,200D/1.1ML)	Biologische Heilmittel Heel Gmbh	02062518	Liquid - Oral	10 D / 1.1 ML	12/31/1994

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

No news found

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.